Atossa Therapeutics, Inc. (ATOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atossa Therapeutics, Inc. on February 20, 2026, covering events occurring on February 19 and February 20, 2026. The Company is a Delaware corporation headquartered in Seattle, Washington, with common stock trading on The Nasdaq Capital Market under the symbol "ATOS."
Key Financial Metrics and Capital Structure
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The primary financial activity disclosed is a new capital raising mechanism:
- Offering Capacity: The Company may offer and sell up to $50,000,000 of common stock.
- Commission: The Sales Agent will receive a commission of up to 3.0% of gross proceeds.
- Use of Proceeds: Intended for clinical development of product candidates, working capital, general corporate purposes, and potentially for licensing, acquiring, or investing in complementary businesses (no current commitments).
Material Changes Versus Prior Period
The filing details two significant changes regarding the Company's equity distribution agreements:
- New Agreement: Entered into an "At the Market" Offering Agreement with Rodman & Renshaw LLC on February 20, 2026.
- Termination: Terminated the prior Open Market Sale Agreement with Jefferies LLC (dated November 19, 2024) effective February 19, 2026.
- Historical Sales: The Company confirmed it did not undertake any sales of common stock under the terminated agreement with Jefferies LLC.
Guidance, Outlook, and Risks
Management Commentary: The Company retains the discretion to suspend offers or terminate the new Sales Agreement at any time. There is no obligation to sell any shares under the new agreement.
Risks and Contingencies: The filing notes that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful. The Company has agreed to indemnify the Sales Agent for certain liabilities under the Securities Act.
Key Facts for Investor Verification
- Verify the current share price and potential dilution impact of a $50,000,000 offering.
- Confirm the status of clinical development programs to assess the immediate need for working capital.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Monitor future filings for actual sales volumes and proceeds generated under the new agreement.